Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Grace Therapeutics, Inc GRCE

Grace Therapeutics, Inc., formerly Acasti Pharma Inc., is a late-stage biopharma company with drug candidates addressing rare and orphan diseases. Its therapeutic pipeline consists of three clinical-stage drug candidates supported by an intellectual property portfolio of over 40 granted and pending patents in various jurisdictions. Its lead drug candidate, GTX-104, is a clinical-stage, novel, injectable formulation of nimodipine being developed for intravenous (IV) infusion in aneurysmal subarachnoid hemorrhage (aSAH) patients to address significant unmet medical needs. GTX-104 provides a convenient IV delivery of nimodipine in the intensive care unit, eliminating the need for nasogastric tube administration in unconscious or dysphagic patients. Its other pipeline drug candidates include GTX-102, which is an oral-mucosal betamethasone spray for the treatment of Ataxia Telangiectasia and GTX-101, which is a topical bio adhesive film-forming bupivacaine spray for Postherpetic Neuralgia.


NDAQ:GRCE - Post by User

Comment by Francine01on Aug 10, 2020 9:10am
178 Views
Post# 31386468

RE:RE:T2 Data Release

RE:RE:T2 Data ReleaseT2 topline release won't be before August 26th for the simple reason that shareholders vote for board directors and stock options plan is closing August 26th. 

Management doesn't want shareholders to kick them out having the T2 topline results in hand.

Also, Jan doesn't want to loose her ridiculus 1,200,000 stock options 0,35$US.. 

For those reasons, they will release T2 topline probably around August 30th, but not before August 26th. 

I hope that all shareholders will vote against Jan as Director and against her ridiculus stock options plan considering that she failed to monitor ph3. 

2 years ago Jan was saved by Neptune vote. Last year she was saved by one significant shareholders. I hope this year, she won't be saved again .. Unfortunetely, she need to leave. She is a poor speaker, she didn't care about retail shareholders and she doesn't want to promote the company. 

GLTA.
<< Previous
Bullboard Posts
Next >>